Praxis precision medicines to participate in upcoming april conferences

Boston, april 05, 2024 (globe newswire) -- praxis precision medicines, inc. (nasdaq: prax), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (cns) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will take part in upcoming conferences in april.

PRAX Ratings Summary

PRAX Quant Ranking